20th February 2025

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir / Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to provisions of Regulation 30 read with Schedule III Part A Para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, we hereby notify that the Company has received final approval from the United States Food and Drug Administration ('USFDA') for the New Drug Application ('NDA') submitted for 'Nilotinib Capsules 50, 150 and 200 mg' on 19th February 2025.

Nilotinib is an oncology category product in capsule form for oral consumption and is used for treatment of philadelphia chromosome positive chronic myeloid leukemia (CML). The product is expected to be launched in FY 2025-26 in the United States of America.

Yours faithfully,
For Cipla Limited
RAJENDRA KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA
Date: 2025.02.20 21:01:10 +05'30'
Rajendra Chopra
Company Secretary

Prepared by: Muskan Jain